Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 phase II trial

Keisuke Uehara, Kazuhiro Hiramatsu, Atsuyuki Maeda, Eiji Sakamoto, Masaya Inoue, Satoshi Kobayashi, Yuichiro Tojima, Yuichiro Yoshioka, Goro Nakayama, Hiroshi Yatsuya, Naoki Ohmiya, Hidemi Goto, Masato Nagino

Research output: Contribution to journalArticlepeer-review

76 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences